EUVIMEDEUVIMED entdecken
LeserbriefKommentar

More Updates to Come of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial: Could the Statistical Methodology Be Further Improved?

Wing H Tong iD, Bart J Mertens

Journal of Clinical Oncology · 2023

DOI: 10.1200/jco.22.02839 ↗

Kurz gefasst

Leserbrief in der Zeitschrift Journal of Clinical Oncology, 2023. Verfasst von Wing H Tong und 1 weiteren Autor:innen. Beteiligte Einrichtung: Wing H. Tong, MD, PhD, MSc, Department of Public Health and Primary Care (PHEG), Leiden University Medical Center, Leiden, the Netherlands, Argos Zor…. Hauptthemen laut MEDLINE: Receptors, Antigen, T-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 8 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tisagenlecleucel (formerly, CTL019), an anti-CD19 chimeric antigen receptor T-cell therapy, is studied intensively in patients with relapsed or refractory B-cell acute lymphoblastic leukemia. 1,2Laetsch et al 3 published important results on the 3-year update of tisagenlecleucel within the ELIANA trial.This has been published as clinical trial updates that provide an opportunity to spread and share the new results as soon as possible from these studies.This phase 2 trial was focused on pediatric and young adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia.This correspondence focuses on the survival analysis that was published by Laetsch et al, 3 in which the authors found that in 79 patients who received tisagenlecleucel from 2015 to 2019, the responses were durable and with a manageable safety profile.In the previously reported primary analysis conducted in 75 patients, with a median follow-up of 13.1 months, the overall remission rate was 81%, with 59% of responders remaining relapse-free at 12 months. 1Although the clinical relevance of the study by Laetsch is clear, some methodological issues can be raised concerning the use of statistical methodology and the choices made in the analysis with potential impact on final conclusions.Some concerns can be raised about some applications of survival analysis methodology in certain parts of the article, specifically the Kaplan-Meier (K-M) analyses. 4he analysis of relapse-free survival is questionable.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Antigen, T-CellPrecursor Cell Lymphoblastic Leukemia-LymphomaChildHumansYoung AdultImmunotherapy, Adoptive

Substanzen

tisagenlecleucelReceptors, Antigen, T-Cell

Autor:innen und Institutionen

  • Wing H. Tong, MD, PhD, MSc, Department of Public Health and Primary Care (PHEG), Leiden University Medical Center, Leiden, the Netherlands, Argos Zorggroep "DrieMaasStede," Center for Specialized Geriatric Care, Schieda…

ORCID-Profile: Wing H Tong

Zitieren

APA

Tong, W. H., & Mertens, B. J. (2023). More Updates to Come of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial: Could the Statistical Methodology Be Further Improved?. Journal of Clinical Oncology. https://doi.org/10.1200/jco.22.02839

Vancouver

Tong WH, Mertens BJ. More Updates to Come of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial: Could the Statistical Methodology Be Further Improved?. Journal of Clinical Oncology. 2023. doi:10.1200/jco.22.02839

BibTeX
@article{Tong2023,
  author = {Tong, Wing H and Mertens, Bart J},
  title = {More Updates to Come of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial: Could the Statistical Methodology Be Further Improved?},
  journal = {Journal of Clinical Oncology},
  year = {2023},
  doi = {10.1200/jco.22.02839}
}
Kostenlos starten →